Icon PLC

The virtual clinical trials market is projected to grow from $11.83 billion in 2024 to $17.43 billion in 2028 at a CAGR of 10.2%, driven by factors like increased adoption of digital technologies and decentralized trials.

The MEA pharmacovigilance market generated USD 260.6 million in 2023 and is projected to grow at a CAGR of 6.5% to USD 404.1 million by 2030. Phase 4 was the largest segment in 2023, while Phase 3 is expected to grow fastest. Saudi Arabia leads in CAGR. The market is driven by biopharmaceutical growth, government initiatives, and regulatory collaborations.

UK in vivo CRO market generated USD 291.5 million in 2023, projected to reach USD 495.4 million by 2030, growing at a CAGR of 7.9%. Small molecule was the largest segment in 2023, while Large Molecule is the fastest growing. The UK market is significant in Europe, driven by preclinical services development and the 3Rs principles, aiming to reduce animal usage in research.

Norway pharmacovigilance market generated USD 55.2 million in 2023, expected to reach USD 89.2 million by 2030 at a CAGR of 7.1%. Phase 4 was the largest segment in 2023, while Phase 1 is the fastest-growing segment. Norway accounted for 0.8% of the global market in 2023, with the U.S. and Germany projected to lead globally and regionally by 2030, respectively.

The global pharmacovigilance market was valued at USD 7.55 billion in 2023 and is projected to reach USD 13.78 billion by 2033, driven by increasing ADRs, drug abuse, and strict regulatory frameworks. Key segments include Phase IV dominating with 75.9% share, contract outsourcing with 60.4%, and oncology with 26.9%. North America leads with 32.5% share, while Asia Pacific is expected to grow significantly. Major players include Accenture, IQVIA Inc., and IBM.

The Clinical Trials market, valued at USD 56,640.7 million in 2023, is projected to reach USD 99,212.0 million by 2031 with a CAGR of 7.4%. Key drivers include demand for innovative therapies, biotechnology advancements, and chronic disease prevalence. Leading players include Iqvia Holdings Inc., Parexel International Corporation, and Charles River Laboratories International, Inc. Notable developments include Q2 Solutions' self-collection safety lab panel and Parexel's Community Alliance Network. The market is segmented by phase, design, indication, and services, with regional analysis covering North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

The article outlines a comprehensive report on the global de-identified health data market, detailing methodology, scope, market variables, trends, segmentation by data type, application, end user, and regional analysis. It also includes a competitive landscape with company profiles and strategic alliances.

The global pharmacovigilance market is expected to reach USD 11.78 billion by 2030, growing at a CAGR of 6.8% due to increasing Adverse Drug Reactions (ADR). Key drivers include ADR-related hospitalizations and the role of PV services in clinical trials. Technological advancements and outsourcing trends are boosting market growth, with biotechnology companies focusing on R&D for novel products.

The global pharmacovigilance market is expected to reach USD 11.78 billion by 2030, growing at a CAGR of 6.8% due to increasing ADR incidents. Key drivers include technological advancements in PV software, outsourcing trends, and regulatory pressures. Biotechnology companies are projected to have the fastest growth, focusing on R&D for novel products. North America leads in market share, while collaborations and acquisitions are strategic moves by industry players.

The Life Sciences BPO market is projected to reach $557.8B by 2030, driven by demand for cost-effective solutions, regulatory complexity, and technological advancements like AI and automation.